AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29877749 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strengthening
Number of subjects: 293
Study 29877749 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care
Number of subjects: 293
Study 29877749 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 293
Study 29088579 — intervention group
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Number of subjects: 306
Study 29088579 — intervention group
Group type: EXPERIMENTAL
Intervention: FX006 16 mg
Number of subjects: 306
Study 29088579 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 306
Study 27049269 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (5 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Number of subjects: 99
Study 27049269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Number of subjects: 99
Study 27049269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Number of subjects: 99
Study 23828877 — intervention group
Group type: EXPERIMENTAL
Intervention: Insole adoption
Number of subjects: 30
Study 23828877 — intervention group
Group type: COMPARATOR
Intervention: No insole
Number of subjects: 30
Study 22198652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (VerSys LD/Fx; Zimmer, Warsaw, IN)
Number of subjects: 130
Study 22198652 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasty (VerSys Beaded FullCoat; Zimmer, Warsaw, IN)
Number of subjects: 130
Study 20001756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg b.i.d.
Number of subjects: 7
Study 20001756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 7
Study 20001756 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 7
Study 18590888 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Contact Cast (TCC)
Number of subjects: 63
Study 18590888 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-shoe
Number of subjects: 63
Study 18590888 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable Cast Walker (RCW)
Number of subjects: 63
Study 18590888 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 63
Study 15531620 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 160
Study 15531620 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 160
Study 15531620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 12039468 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol pretreatment
Number of subjects: 132
Study 12039468 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 132
Study 12039468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study 10360848 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 48
Study 10360848 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg epidural neostigmine
Number of subjects: 48
Study 10360848 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg epidural neostigmine
Number of subjects: 48
Study 10360848 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microg/kg epidural neostigmine
Number of subjects: 48
Study 8943972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antroduodenal manometry in patients with gastrointestinal motility disorders
Number of subjects: 95
Study 8943972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antroduodenal manometry in parenteral-nutrition-dependent children
Number of subjects: 95
Study 8458317 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral vitamin K1 supplement (average 88 micrograms)
Number of subjects: 36
Study 8458317 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 36
Study 2429279 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g IV flucloxacillin 1 hour before the operation, then 1 g perorally every 8 hours for the next five days
Number of subjects: 106
Study 2429279 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions and tablets given at the same schedule as SPG
Number of subjects: 106
Study 31451025 — intervention group
Group type: EXPERIMENTAL
Intervention: Adducted arm position (Group A)
Number of subjects: 60
Study 31451025 — intervention group
Group type: COMPARATOR
Intervention: Abducted arm position (Group B)
Number of subjects: 60
Study 31047340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 357
Study 27604226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit One
Number of subjects: 29
Study 27604226 — intervention group
Group type: EXPERIMENTAL
Intervention: Jawbone UP
Number of subjects: 29
Study 27604226 — intervention group
Group type: COMPARATOR
Intervention: ActiGraph GT3X+
Number of subjects: 29
Study 25933493 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of α-linolenic acid (ALA) for 60 days
Number of subjects: 20
Study 25933493 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 20
Study 23042976 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon therapy
Number of subjects: 214
Study 21554881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of arginine vasopressin (AVP) during tasks with social evaluative threat.
Number of subjects: 0
Study 21554881 — intervention group
Group type: COMPARATOR
Intervention: Intranasal administration of arginine vasopressin (AVP) during tasks without social evaluative threat.
Number of subjects: 0
Study 21554881 — intervention group
Group type: COMPARATOR
Intervention: Placebo during tasks without social evaluative threat.
Number of subjects: 0
Study 17997387 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing pointing action
Number of subjects: 0
Study 16595209 — intervention group
Group type: EXPERIMENTAL
Intervention: EBMS group counseling (n = 69)
Number of subjects: 227
Study 16595209 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 115)
Number of subjects: 227
Study 14767408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropical climate (TR, 30.4 degrees C, 70% rh)
Number of subjects: 14
Study 14767408 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral climate (TN, 23.1 degrees C, 53% rh)
Number of subjects: 14
Study 14767408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropical climate (TR)
Number of subjects: 14
Study 14767408 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral climate (TN)
Number of subjects: 14
Study 11970745 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg/day
Number of subjects: 0
Study 11970745 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 0
Study 7673540 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 0
Study 7673540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (BT)
Number of subjects: 0
Study 7673540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dermatological educational program and cognitive-behavioral treatment (DEBT)
Number of subjects: 0
Study 7673540 — intervention group
Group type: COMPARATOR
Intervention: Dermatological educational program (DE)
Number of subjects: 0
Study 7673540 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 0
Study 2119558 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPN (perdialytic parenteral nutrition)
Number of subjects: 26
Study 2119558 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPN
Number of subjects: 26
Study 2119558 — intervention group
Group type: COMPARATOR
Intervention: Control (no PDPN)
Number of subjects: 26
Study 6783431 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 12
Study 6783431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30707847 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention (EI)
Number of subjects: 46
Study 30707847 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Intervention (LI)
Number of subjects: 46
Study 28672318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling for 72 hours at 33.5°C (n=95)
Number of subjects: 364
Study 28672318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling for 120 hours at 33.5°C (n=96)
Number of subjects: 364
Study 28672318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling for 72 hours at 32.0°C (n=90)
Number of subjects: 364
Study 28672318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling for 120 hours at 32.0°C (n=83)
Number of subjects: 364
Study 25796322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 21
Study 25796322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Number of subjects: 21
Study 25796322 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 25796322 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 21
Study 23194445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung lavage using two aliquots of 15 mL/kg of dilute surfactant
Number of subjects: 30
Study 21883879 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression duplex ultrasound (CDU) screening at about 7-10 days after enrollment
Number of subjects: 5632
Study 21883879 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression duplex ultrasound (CDU) screening at about 25-30 days after enrollment
Number of subjects: 5632
Study 21883879 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT detected on the first CDU scan
Number of subjects: 5632
Study 21883879 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT characteristics
Number of subjects: 5632
Study 21883879 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT regression in patients with a DVT detected on the first CDU scan who had a second scan
Number of subjects: 5632
Study 19261275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with mild ovarian hyperstimulation
Number of subjects: 73
Study 19261275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) without stimulation
Number of subjects: 73
Study 19261275 — intervention group
Group type: COMPARATOR
Intervention: Sequential timed natural intercourse
Number of subjects: 73
Study 16709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 g/day subcutaneously)
Number of subjects: 104
Study 16709314 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (100 IU/day subcutaneously)
Number of subjects: 104
Study 16709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 104
Study 16709314 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin
Number of subjects: 104
Study 15321935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anaesthesia (3 ml injection of lidocaine 2% and bupivacaine 0.75%)
Number of subjects: 210
Study 15321935 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthesia (four doses of proxymethocaine 0.5%)
Number of subjects: 210
Study 11259889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (n = 29)
Number of subjects: 60
Study 11259889 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (n = 31)
Number of subjects: 60
Study 9024745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 20 weeks
Number of subjects: 0
Study 9024745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 0
Study 9024745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7880667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg i.v.
Number of subjects: 60
Study 7880667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.05 mg kg‐1 i.v.
Number of subjects: 60
Study 7880667 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 60
Study 3364074 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon (2 X 10(6) I. U. daily)
Number of subjects: 0
Study 3364074 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon (6 X 10(6) to 9 X 10(6) I. U. daily)
Number of subjects: 0
Study 3364074 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon (all doses)
Number of subjects: 0
Study 30840643 — intervention group
Group type: EXPERIMENTAL
Intervention: Buying-shopping disorder (BSD) group
Number of subjects: 39
Study 30840643 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) group
Number of subjects: 39
Study 30840643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot-probe paradigm (DPP), Implicit Association Task (IAT), Go/nogo-task (GNG)
Number of subjects: 39
Study 27919570 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhalyzer D (EM)
Number of subjects: 182
Study 27919570 — intervention group
Group type: COMPARATOR
Intervention: EasyOne Pro (NDD)
Number of subjects: 182
Study 25783889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 94
Study 25783889 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (Control)
Number of subjects: 94
Study 24002145 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized hyaluronic acid-based gel (Restylane® Vital Light) administered via micropuncture injector
Number of subjects: 30
Study 21352939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine (60 μg HA per strain)
Number of subjects: 0
Study 21352939 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine (15 μg HA per strain)
Number of subjects: 0
Study 18166095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% doxycycline hyclate bioabsorbable barrier + demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 3
Study 18166095 — intervention group
Group type: COMPARATOR
Intervention: Poly(DL‐lactide) PLA barrier without doxycycline + DFDBA
Number of subjects: 3
Study 18166095 — intervention group
Group type: COMPARATOR
Intervention: DFDBA alone
Number of subjects: 3
Study 17011942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (10-20 mg daily)
Number of subjects: 7832
Study 17011942 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 7832
Study 12590005 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Kava-Kava 100 mg/day
Number of subjects: 68
Study 12590005 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Kava-Kava 200 mg/day
Number of subjects: 68
Study 12590005 — intervention group
Group type: COMPARATOR
Intervention: Calcium (control)
Number of subjects: 68
Study 12590005 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Kava-Kava (both doses)
Number of subjects: 68
Study 10813713 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF administered at a dose of 5 microg/kg/day at 10 a.m.
Number of subjects: 24
Study 10813713 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF administered at a dose of 5 microg/kg/day at 10 p.m.
Number of subjects: 24
Study 8623944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg added to 180 mg propofol
Number of subjects: 89
Study 8623944 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 1 mg 30 s prior to propofol
Number of subjects: 89
Study 8623944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 89
Study 1449302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of metoprolol
Number of subjects: 21
Study 1449302 — intervention group
Group type: COMPARATOR
Intervention: Oral dose of metoprolol (control group)
Number of subjects: 21
Study 2866492 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg once daily
Number of subjects: 38
Study 2866492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29857012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser-assisted methyl aminolevulinate photodynamic therapy (AFL-MAL-PDT)
Number of subjects: 60
Study 29857012 — intervention group
Group type: COMPARATOR
Intervention: Conventional methyl aminolevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 60
Study 26166140 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200mg daily)
Number of subjects: 150
Study 26166140 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen (180 mg daily) plus Lansoprazole (15mg daily)
Number of subjects: 150
Study 25070302 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (eAT)
Number of subjects: 464
Study 25070302 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting and Supportive Care (WWSC)
Number of subjects: 464
Study 22309271 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC(2%LUV)
Number of subjects: 15
Study 22309271 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC(2%EPI)
Number of subjects: 15
Study 22309271 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC(3%)
Number of subjects: 15
Study 22309271 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC(3%LUV)
Number of subjects: 15
Study 20530322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab administered at 375 mg/m² weekly for 4 doses
Number of subjects: 30
Study 17938330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral supraglottic laryngectomy by carbon dioxide laser followed by planned postoperative radiotherapy
Number of subjects: 34
Study 15545669 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy (CONC RT)
Number of subjects: 309
Study 15545669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential radiotherapy (SEQ RT)
Number of subjects: 309
Study 11932900 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 36
Study 11932900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-MIBI SPECT
Number of subjects: 36
Study 11932900 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 36
Study 11932900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CT and Tc-MIBI SPECT
Number of subjects: 36
Study 9459335 — intervention group
Group type: EXPERIMENTAL
Intervention: 677 C-->T mutation in the MTHFR gene
Number of subjects: 337
Study 7829706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg two or three times a day for 14 days)
Number of subjects: 86
Study 7829706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg three times daily for 20 days)
Number of subjects: 86
Study 7829706 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (500 mg four times a day for 14 days)
Number of subjects: 86
Study 7829706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (14 days)
Number of subjects: 86
Study 2650879 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg at the first symptom of the attack, total allowed 1250 mg per 24 h
Number of subjects: 32
Study 2650879 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 32
Study 2650879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1090416 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg lorazepam intravenously
Number of subjects: 20
Study 1090416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30732618 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal treatment protocol (3 μg/kg)
Number of subjects: 5278
Study 30732618 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol (2 μg/kg)
Number of subjects: 5278
Study 27565000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 795
Study 27565000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 795
Study 27565000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795
Study 26759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (bed lowered and step stool readily available)
Number of subjects: 56
Study 26759667 — intervention group
Group type: COMPARATOR
Intervention: Control (bed raised and step stool accessible, but concealed)
Number of subjects: 56
Study 26759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and Control (arm position at 90-degree angle)
Number of subjects: 56
Study 26759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Step stool utilization
Number of subjects: 56
Study 26759667 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject characteristics (height, weight group, gender)
Number of subjects: 56
Study 23159063 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 174
Study 23159063 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 174
Study 23159063 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 174
Study 21612433 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic retroperitoneal pyelolithotomy (LRP)
Number of subjects: 105
Study 21612433 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 105
Study 19376306 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel therapy (additional loading dose followed by 150 mg daily for 6 months)
Number of subjects: 2800
Study 19376306 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance clopidogrel therapy (75 mg daily for 6 months)
Number of subjects: 2800
Study 19376306 — intervention group
Group type: COMPARATOR
Intervention: Standard clopidogrel therapy (75 mg daily for 6 months) for patients without high residual reactivity
Number of subjects: 2800
Study 18453220 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-axilloareolar approach
Number of subjects: 238
Study 18453220 — intervention group
Group type: COMPARATOR
Intervention: Trans-thoracoareolar approach
Number of subjects: 238
Study 14997196 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and protein dense oral supplement enriched with n-3 fatty acids (EPA)
Number of subjects: 24
Study 14997196 — intervention group
Group type: COMPARATOR
Intervention: Control energy and protein dense oral supplement
Number of subjects: 24
Study 11292151 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines (subunit vaccine with MF59 - a-SUV)
Number of subjects: 635